Cytel to hold Complex Innovative Trial Design Symposium

18 Oct 2019

Experts to discuss innovative solutions to rare disease clinical trials.

Cytel has announced that the Complex Innovative Trial Design Symposium and East Training will take place 6–7 November at Alexion’s headquarters in Boston, Massachusetts. The event will bring together industry-leading experts to discuss innovative solutions to pressing challenges including rare disease clinical trials.

Cytel to hold Complex Innovative Trial Design Symposium

Cytel has hosted the annual Complex Innovative Trial Design Symposium and East Training since 2011 to connect global thought leaders and innovators from the pharmaceutical industry in order to facilitate the exchange of ideas and reveal new insights on the latest developments in adaptive clinical trial designs. The event also plays a key role in guiding the continual evolution of Cytel’s East platform, the industry-standard software for adaptive clinical trial design and analysis. Amongst the list of guest speakers will be leaders from Pfizer, Takeda and Servier, as well as statistical experts from Cytel, Alexion and Axio.

This year’s symposium will focus on overcoming the acute challenges associated with clinical trials for rare diseases, with an emphasis on how innovative, adaptive clinical trial designs can be exploited to maximize trial efficiency, accommodate specialized data requirements and enhance rare disease trial success rates. The latest insights and detailed case studies will be shared through a series of engaging presentations, and participants will also have the opportunity to actively participate in an East training session on day two.

Currently, rare diseases affect around 350 million patients worldwide, with 90% of rare diseases still without an approved therapy. In addition, scarce patient resources and lack of disease knowledge regarding the best endpoints and treatment effect size makes clinical development for new and effective therapeutics for rare diseases especially difficult.

“To overcome the myriad of clinical trial pain points presented by rare diseases, we need to think creatively and adopt a knowledge-sharing approach to the clinical development process,” said Yannis Jemiai, Chief Scientific Officer at Cytel. “The symposium will offer a key space to facilitate peer-to-peer exchanges, ideation, and sharing of practical solutions. We are driving forward novel experimental designs and statistical approaches for better clinical outcomes in patients with rare disorders.”

Delegates will have the opportunity to learn about a range of novel methodological advancements in the rare disease trial space, including:

  • The use of natural history data in clinical trials for rare diseases
  • The PREVENT trial for Neuromyelitis optica spectrum disorder (NMOSD)
  • Historical control information borrowing.
  • The in-depth East software training workshop that will take place on day two will guide participants through the extensive range of powerful trial design tools within East, keeping them up to date on the software platform’s latest developments.

    Read More

    Related news

    Europe predicted to surpass the US in biologic manufacturing capacity by 2023

    Europe predicted to surpass the US in biologic manufacturing capacity by 2023

    6 Nov 2019

    Demand for biological manufacturing is growing faster than capacity growth.

    Read more 
    China on course for 'massive' bio capacity shortfall

    China on course for 'massive' bio capacity shortfall

    4 Nov 2019

    A shortage of qualified personnel may be a drag factor in cell and gene therapies; in China 100,00L of capacity will need to be added every year to meet bio demand.

    Read more 
    German pharma benefiting from a Brexit boost?

    German pharma benefiting from a Brexit boost?

    24 Oct 2019

    Germany establishes itself as Europe's leading pharma market in 2019.

    Read more 
    The talk of the show?

    The talk of the show?

    23 Oct 2019

    Outsourcing, biologics, generics and patient compliance look set to get tongues wagging at this year's CPhI WW.

    Read more 
    ‘FDA should withdraw ANDAs’ says expert

    ‘FDA should withdraw ANDAs’ says expert

    21 Oct 2019

    CPhI Worldwide's Annual Report suggests repeat offenders of regulatory infringements should be barred from importing into the US.

    Read more 
    Finalists announced for this year's CPhI Worldwide Awards

    Finalists announced for this year's CPhI Worldwide Awards

    17 Oct 2019

    The winners’ shortlist is packed with 40 of the industry’s most innovative companies and individuals who are shaping the future of pharma.

    Read more 
    One-stop-platform for plant-based nutraceuticals

    One-stop-platform for plant-based nutraceuticals

    2 Oct 2019

    In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.

    Read more 
    Industry on the brink of a new age of smart pharma manufacturing

    Industry on the brink of a new age of smart pharma manufacturing

    27 Sep 2019

    Report predicts tomorrow’s biggest industry winners will need to invest now ahead of the curve.

    Read more 
    Huge boom in Korean Pharma reported at CPhI Korea

    Huge boom in Korean Pharma reported at CPhI Korea

    20 Sep 2019

    Event sees new Memorandum of Understanding signed by PROLMED and KPTA.

    Read more 
    Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

    Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

    9 Sep 2019

    Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

    Read more